Dr. Bruno Santos joins Exobiosphere as the Director of R&D

LUXEMBOURG – Exobiosphere is at the forefront of biotechnology innovation, leveraging the unique conditions of space to revolutionize drug discovery. This vision takes another step forward with the addition of Dr. Bruno Santos as the Director of Research & Development.

Bruno brings over a decade of experience in in vitro disease modeling, high-throughput screening, high-content imaging, early drug discovery, and lab automation. He holds a Bachelor’s degree in Biotechnology from Portugal, two Master’s degrees (Integrated Systems Biology from the University of Luxembourg and Cancer Biology from Roswell Park Cancer Institute, NY), and a PhD in Molecular Neuroscience from the University of Luxembourg. While at the Luxembourg Center for Systems Biomedicine, Bruno developed a cutting-edge disease modeling and screening platform and researched cancer, Parkinson’s, and other diseases. Having worked with academia, biotech CROs, and big pharma, Bruno brings a unique blend of research and commercial experience to the team.

“Bruno Santos’s joining marks a pivotal moment for Exobiosphere,” said Kyle Acierno, CEO of Exobiosphere. “His expertise in molecular neuroscience and biotech automation will drive our mission to become the first space-based Contract Research Organization forward.”

Bruno’s perspective? “This is the frontier of biotech. Leveraging space for breakthroughs is the future, and I am very excited to be part of a team making that happen.”

About Exobiosphere:

Exobiosphere is pushing the boundaries of biotechnology in space, using microgravity to unlock the next generation of drug discovery and skincare. By harnessing high-throughput testing and space-based research, we're developing game-changing formulations and therapies to solve the biggest challenges in pharma and beauty. It’s about innovation, scalability, and transforming industries—pushing the limits of what’s possible to create real-world solutions that impact both Earth and beyond.